Comparative effects of atorvastatin and rosuvastatin on inflammatory biomarkers: a systematic review and meta-analysis of randomized head-to-head trials.

BMC Cardiovasc DisordSep 10, 2026 (epub)
Clinical ResearchCardiologyInternal Medicine (General)Open access

Abu Omayer, Mohamed I Mohamed, Maryam Shahid et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis of 35 randomized controlled trials (n=6,148) compared the effects of atorvastatin and rosuvastatin on inflammatory biomarkers. The analysis revealed that rosuvastatin significantly reduced C-reactive protein (CRP) levels more than atorvastatin, with a mean difference of -0.16 mg/L (95% CI: -0.28 to -0.03; p=0.01).

Key findings

  • Rosuvastatin reduced CRP levels more than atorvastatin, with a mean difference of -0.16 mg/L.
  • The standardized mean difference for CRP reduction favored rosuvastatin at -0.17.
  • No significant differences were found for IL-6, adiponectin, or TNF-alpha.
  • Sensitivity analysis among low risk-of-bias studies showed a significant CRP reduction of -0.08 mg/L.

Why it matters

Understanding the comparative effects of atorvastatin and rosuvastatin on inflammatory biomarkers can help clinicians tailor statin therapy to optimize cardiovascular outcomes, particularly in patients with elevated baseline inflammation.

Source

PubMed · PMID 42723012Free full text on PubMed Central

Published in BMC Cardiovasc Disord. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.